melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To further determine the significance of this observation, 17 melanoma cell lines sensitive or resistant to the antiproliferative effects of IFN-alpha2 and IFN-beta, as well as 30 melanoma patient samples, were analyzed for Stat1 levels by either Western blot analysis or immunohistochemistry.
|
12060499 |
2002 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These observations, together with our previous findings showing the importance of IFN-alpha-T cell interactions in the generation of an antitumor response in mouse models, underline the interest of using type I IFN in gene therapy strategies for the treatment of human melanoma.
|
10673721 |
2000 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In a previous study on melanoma cell lines we found that greatest sensitivity to IFN was found in cell lines with the greatest number of copies of chromosome 9p, where the IFN gene family is located.
|
10596911 |
1999 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Direct intratumoral injection of 100 microg of a IFN-omega pDNA DMRIE/DOPE complex (1:1 DNA:DMRIE mass ratio) for 6 consecutive days resulted in a significant reduction in the tumor volume of NIH: OVCAR-3 ovarian carcinoma or A375 melanoma (P = 0.02).IFN-omega pDNA delivered by i.m. injection also had an antitumor effect.
|
10463608 |
1999 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results support a role for IFN-gamma priming in up-regulating ISGF3, thereby augmenting the responsiveness of IFN-resistant melanoma cell lines to type I IFN and providing a molecular basis and justification for using sequential IFN therapy, as proposed by others, to enhance the use of IFNs in the treatment of melanoma.
|
9605150 |
1998 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conclude that a defect in the level of STAT1 and possibly all three ISGF3 components in IFN-resistant human melanoma cells may be a general phenomenon responsible for reduced cellular responsiveness of melanomas to IFNs.
|
9353349 |
1997 |
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results show that there is a specific disruption of IFN-alpha gene activation rather than IFN-beta in melanoma lines and suggest that this is due to disruption of a trans-acting IFN-alpha gene transcription factor.
|
7664286 |
1995 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings, if confirmed, might indicate that IFN and glucocorticoid hormones are not mutually exclusive in the management of human melanoma.
|
7543821 |
1995 |
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Heterozygous losses were found in 8/14 (57%) fresh melanoma biopsy DNAs with the smallest region of overlap (SRO) being between IFNA and D9S169.
|
8108124 |
1994 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We plan to use gamma-IFN--transduced autologous tumor cells to boost host immune responses as a potential therapy for human melanoma.
|
8024193 |
1994 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human melanoma tumor cell lines were transduced with a MoMLV-based retroviral vector carrying the human gamma IFN gene.
|
7621248 |
1994 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used two highly informative (CA)n repeats, D9S126 and IFNA, previously implicated in familial malignant melanoma (MLM), to conduct linkage analysis.
|
8116618 |
1994 |
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These data confirm the existence of a melanoma susceptibility gene on 9p and indicate that this locus most probably lies outside of the IFNA-D9S126 interval.
|
8213823 |
1993 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We previously reported that interleukin 4 (IL-4) and either tumor necrosis factor alpha (TNF) or interferon gamma (IFN) synergistically inhibit melanoma cell growth and induce cell differentiation.
|
8242663 |
1993 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The unique de novo and IFN-modified antigenic phenotype of cultures derived from different patients indicates that the antigenic phenotype displayed by melanoma cultures grown in vitro is genetically determined.
|
2118485 |
1990 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, the level of Mx-homologous protein induced during IFN therapy is not a predictive marker for an antitumor response in malignant melanoma.
|
1701809 |
1990 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Binding studies indicated the presence of 2,980 +/- 170 receptors per cell, each with an apparent Kd of (8.4 +/- 1.3) X 10(-11) M. Results from competitive binding studies suggested that Hs294T cells possess at least two types of IFN receptors: one which binds IFN-alpha A and IFN-beta 1 and another to which IFN-gamma binds.
|
6319748 |
1984 |